Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: Phase 3 Study of ION582 in Angelman Syndrome
NCT06914609Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Aug 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of obudanersen in Angelman syndrome (AS) (4 cohorts), sponsored by Ionis Pharmaceuticals. Primary endpoint: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 Without Caregiver Input at Week 52. Started Jun 2025; status: active, not recruiting.
02
Drugs
obudanersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT06914609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914609.